Focal therapy (FT) for the treatment of localized prostate cancer offers an alternative strategy for men seeking active treatment. Although relatively new, existing studies suggest that the majority of men who undergo FT tend to maintain levels of genito-urinary function that are indistinguishable from their pre-treatment status. However, as part of the shared decision making process, men need to balance good tolerability against a greater risk of recurrence given that much of the prostate remains intact after FT. In order to explore this trade-off, we used decision modelling. Our findings show that the burden of functional complications associated with radical prostatectomy (RP) is considerable, as an average of 243 days of perfect health are lost per patient due to treatment-induced urinary incontinence and erectile dysfunction. Given this effectiveness gap in current care, we explored by how much mortality -as worst-case outcome of disease progression -could increase to still result in net health benefit. To do this we mapped the net health benefit/loss of FT, in comparison to RP, for different levels of function preservation and increases in mortality. We believe our modelling exercise might help inform future studies that seek to enhance our understanding of how men make treatment decisions.
In 2018, the European Association of Urology (EAU) published a position paper on focal therapy (FT) in primary localised prostate cancer (PCa) [1] . The association states that FT can only be considered beneficial to patients in the long run if it provides fewer functional complications and at least equivalent survival efficacy, compared to current care. However, whole-gland approaches to PCa, such as radical prostatectomy (RP), are known to result in functional complications for a significant number of patients, impairing their quality of life for the rest of their (often relatively long) lives. Consequently, if it is true that FT results in fewer functional complications (a reward), perhaps some men are willing to trade-off a degree of increased probability (versus standard care) of disease progression (a risk). Such a trade-off has an inherent temporal element in that treatment-related functional complications are both inevitable and immediate, whereas any compromise in oncological outcome is going to be deferred and will be confined to a minority. In this perspective article we used decision modelling to conduct an evidence-based thought experiment that explores this trade-off. Our intention is not to be exhaustive, but rather to enhance our understanding of decision making in this space. We modelled existing evidence on RP to explore (1) how much health is lost to functional complications associated with prostate cancer treated with RP, and (2) by how much the mortality of FT-as worst-case outcome of disease progression-could increase to still result in net health benefit.
Let us assume a hypothetical target population of PCa patients with an average age of 65 whose risk profile makes them eligible for both RP and FT (e.g. men with PSA ≤ 15 ng/mL and a maximum Gleason ≤ 3 + 4 that is unilateral [2] ). In modelling complication-related versus mortality-related losses in health, we are interested in both the quality and duration of patients' lives. The quality-adjusted life-year (QALY) provides a metric that corrects the duration of patients' lives for the quality (utility) in which that life is spent-allowing for trade-offs [3] . For example, 10 QALYs means both 10 life-years spent in perfect health (utility of 1) and 20 life-years spent in mediocre health (utility of 0.5).
In a decision model we synthesised the available evidence and quantified the current loss in QALYs due to functional complications after RP [4] . The model structure is shown in Appendix Fig. 1 and 2 . Following treatment, patients may or may not experience functional complications. These complications are associated with reduced quality of life. The model then simulated yearly cycles in which patients remained in their starting health state, improved (at year 2), or died-all with associated quality of life. At the end of the lifetime horizon, the average QALYs were calculated.
Regarding functional complications, we focused on urinary incontinence (UI) and erectile dysfunction (ED), though we appreciate there are others. We used two studies that reported UI and ED rates after robot-assisted RP specifically [5, 6] . Since we expected the UI and ED rates to contain overlap, we estimated the probability that patients have both UI and ED (see Appendix Table 1 ). We found quality of life estimates for UI, ED, and UI and ED both [7] . Regarding survival, we used 18-year survival data reported by Bill-Axelson et al. to estimate mortality after RP [8] . As potential risk of FT, we chose to model mortality as a worstcase proxy of disease progression. We operationalised increased mortality of FT as a relative risk (RR) of dying after FT, compared to RP, and assumed that this RR is applied for up to 18 years after treatment. All parameter estimates and their sources are listed in Appendix Table 2 .
To visualise a potential trade-off between duration and quality of life, we searched for the point of QALY indifference where the QALYs that could be gained by preventing complications (by FT, compared to RP) no longer outweigh the QALYs lost to increased mortality (see Fig. 1 ). Figure 1 can be interpreted as follows. If FT prevents 50% of all functional complications compared to RP, the yearly relative risk of dying should remain below 1.075 (i.e. 7.5% increase in mortality) to result in expected health benefit. If FT prevents 70% of complications, the point of QALY indifference increases to a RR of 1.1. To translate this to specific focal innovations, if, as reported by Valerio et al. [9] , focal HIFU prevents UI by 88% and ED by 84%, the point of QALY indifference lies at a 13% increased risk of dying. Figure 1 can also be used for calculating the expected health benefit of an innovation in specific scenarios. For example, a 'perfect' treatment that eliminates all complications, with mortality rates equal to RP, would yield an additional 243 days in perfect health per patient. If it reduces functional complications by 50% and increases mortality by 5%, there is still a net health benefit of 39 days in perfect health. See Appendix Figures 3 and 4 for similar analyses when only UI or only ED were considered.
The implication of this modelling study is that radical prostatectomy leaves room for improvement in terms of functional complication profile. RP is associated with functional complications that affect patients' quality of life quite considerably. Therefore, some level of risk (here, increased mortality) might be tolerable when considering focal innovations that could reduce the burden of complications. We believe this perspective can stimulate the debate surrounding focal therapy.
In reality, both PCa itself and the treatment trajectory are more complex than we chose to incorporate in our model. Our relatively simple model visualizes the risk-reward balance, and thereby informs decision making regarding FT, based on the challenges of currently available treatment. Ultimately, shared decision-making between doctor and patient may facilitate a personal value trade-off between expected duration and quality of life. Fig. 1 Exploratory analysis of health benefit/loss of a hypothetical focal treatment (FT) compared to radical prostatectomy (RP). On the x-axis, the relative risk of dying, when comparing FT to RP, is varied from 1 (equal mortality rate) to 1.15 (15% increase in mortality rate). On the y-axis, the relative reduction in both urinary incontinence (UI) and erectile dysfunction (ED) is varied from 0% (no complication reduction compared to RP) to 100% (FT prevents all RP complications). The numbers in the graph represent days in perfect health lost/ gained, obtained by converting the quality-adjusted life-years (QALYs) obtained from the model to days in perfect health. Green numbers indicate the number of days in perfect health gained by FT, red numbers indicate the number of days in perfect health lost by FT. The zeros in black indicate points of indifference, where FT and RP result in equal health
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